摘要
慢性血栓栓塞性肺动脉高压被归类为第4类肺动脉高压。肺动脉内膜剥脱术是CTEPH的首选治疗。可溶性鸟苷酸环化酶刺激剂(利奥西呱)是首个被美国FDA批准用于治疗CTEPH的靶向药物,随着介入治疗的发展,经皮球囊肺动脉成形术逐渐成为无法行肺动脉内膜剥脱术、术后仍持续高压或复发患者的一种新选择。文章就经皮球囊肺动脉成形术发展过程、适应证、治疗流程及并发症作一综述。
Chronic thromboembolic pulmonary hypertension is classifed as Group-4 pulmonary hypertension caused by organized thrombi in pulmonary arteries.Pulmonary endarterectomy is the preferred treatment for CTEPH.The soluble guanylate cyclase stimulator(riociguat)is the sole FDA-licensed drug for the treatment of CTEPH.With the development of interventional therapy,balloon pulmonary angioplasty has gradually become new therapy for patients with inoperable CTEPH or residual or recurrent pulmonary hypertension following PEA.This article reviews the development process,indications,treatment procedures and complications of BPA to provide a better understanding and evaluation of BPA as a treatment option in CTEPH patients.
作者
周阳逸
顾建平
汪涛
Zhou Yangyi;Gu Jianping;Wang Tao(Department of Interventional Radiology,Affiliated Nanjing Hospital of Nanjing Medical University,Jiangsu Nanjing 210006,China)
出处
《中华介入放射学电子杂志》
2020年第2期184-188,共5页
Chinese Journal of Interventional Radiology：electronic edition
关键词
慢性血栓栓塞性肺动脉高压
球囊肺动脉成形术
肺栓塞
Chronic thromboembolic pulmonary hypertension
Balloon pulmonary angioplasty
Pulmonary embolism
